"23" . . "Karcinom pankreatu je jednou z nejz\u00E1va\u017En\u011Bj\u0161\u00EDch forem n\u00E1dorov\u00E9ho onemocn\u011Bn\u00ED s velmi vysokou mortalitou, kter\u00E1 ho v \u010CR \u0159ad\u00ED na \u010Dtvrtou p\u0159\u00ED\u010Dku v p\u0159\u00ED\u010Din\u00E1ch \u00FAmrt\u00ED na n\u00E1dorov\u00E1 onemocn\u011Bn\u00ED. Cytostatikum ze skupiny nukleosidov\u00FDch analog - gemcitabin - pat\u0159\u00ED v sou\u010Dasn\u00E9 dob\u011B mezi \u0161iroce u\u017E\u00EDvan\u00E9 prepar\u00E1ty v onkologick\u00E9 l\u00E9\u010Db\u011B a zejm\u00E9na u karcinomu pankreatu. Vznik l\u00E9kov\u00E9 rezistence v\u00FDrazn\u011B limituje klinick\u00E9 vyu\u017Eit\u00ED gemcitabinu, stejn\u011B jako ostatn\u00EDch cytostatik."@cs . "CZ - \u010Cesk\u00E1 republika" . . . "Role membr\u00E1nov\u00FDch transport\u00E9r\u016F v chemorezistenci karcinomu pankreatu p\u0159i terapii gemcitabinem"@cs . . "5" . . . "285667" . "0862-495X" . "[3CC592F128DF]" . "5"^^ . "The role of membrane transporters in cellular resistance of pancreatic carcinoma to gemcitabine"@en . "Role membr\u00E1nov\u00FDch transport\u00E9r\u016F v chemorezistenci karcinomu pankreatu p\u0159i terapii gemcitabinem" . . "Moheln\u00EDkov\u00E1-Ducho\u0148ov\u00E1, Beatrice" . . "The role of membrane transporters in cellular resistance of pancreatic carcinoma to gemcitabine"@en . "2"^^ . "V" . "Klinick\u00E1 onkologie" . . "RIV/75010330:_____/10:00008954" . . "2"^^ . "Role membr\u00E1nov\u00FDch transport\u00E9r\u016F v chemorezistenci karcinomu pankreatu p\u0159i terapii gemcitabinem" . "RIV/75010330:_____/10:00008954!RIV11-MZ0-75010330" . . "Sou\u010Dek, Pavel" . . "Karcinom pankreatu je jednou z nejz\u00E1va\u017En\u011Bj\u0161\u00EDch forem n\u00E1dorov\u00E9ho onemocn\u011Bn\u00ED s velmi vysokou mortalitou, kter\u00E1 ho v \u010CR \u0159ad\u00ED na \u010Dtvrtou p\u0159\u00ED\u010Dku v p\u0159\u00ED\u010Din\u00E1ch \u00FAmrt\u00ED na n\u00E1dorov\u00E1 onemocn\u011Bn\u00ED. Cytostatikum ze skupiny nukleosidov\u00FDch analog - gemcitabin - pat\u0159\u00ED v sou\u010Dasn\u00E9 dob\u011B mezi \u0161iroce u\u017E\u00EDvan\u00E9 prepar\u00E1ty v onkologick\u00E9 l\u00E9\u010Db\u011B a zejm\u00E9na u karcinomu pankreatu. Vznik l\u00E9kov\u00E9 rezistence v\u00FDrazn\u011B limituje klinick\u00E9 vyu\u017Eit\u00ED gemcitabinu, stejn\u011B jako ostatn\u00EDch cytostatik." . "Role membr\u00E1nov\u00FDch transport\u00E9r\u016F v chemorezistenci karcinomu pankreatu p\u0159i terapii gemcitabinem"@cs . . "Pancreatic carcinoma is one of the most serious forms of cancer, with a very high mortality rate, and is the fourth leading cause of cancer-related death in the Czech Republic. The etiology and molecular pathogenesis of the disease is still poorly understood. Gemcitabine is a cytotoxic nucleoside analog, which is widely used in the treatment of malignancies, and in particular in pancreatic carcinoma. Resistance developed to nucleoside analogs limits their clinical use, just like in the case of any other cytostatics."@en . . . "pancreas; cancer; gemcitabine"@en .